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Abstract
Depression is more frequent among individuals exposed to traumatic events. Both trauma exposure and depression are
heritable. However, the relationship between these traits, including the role of genetic risk factors, is complex and poorly
understood. When modelling trauma exposure as an environmental influence on depression, both gene-environment
correlations and gene-environment interactions have been observed. The UK Biobank concurrently assessed Major
Depressive Disorder (MDD) and self-reported lifetime exposure to traumatic events in 126,522 genotyped individuals of
European ancestry. We contrasted genetic influences on MDD stratified by reported trauma exposure (final sample size
range: 24,094–92,957). The SNP-based heritability of MDD with reported trauma exposure (24%) was greater than MDD
without reported trauma exposure (12%). Simulations showed that this is not confounded by the strong, positive genetic
correlation observed between MDD and reported trauma exposure. We also observed that the genetic correlation between
MDD and waist circumference was only significant in individuals reporting trauma exposure (rg= 0.24, p= 1.8 × 10−7
versus rg=−0.05, p= 0.39 in individuals not reporting trauma exposure, difference p= 2.3 × 10−4). Our results suggest
that the genetic contribution to MDD is greater when reported trauma is present, and that a complex relationship exists
between reported trauma exposure, body composition, and MDD.
Introduction
Depression is among the most common mental illnesses
worldwide and accounts for 5.5% of all years lost through
disability globally [1]. In England ~28% of individuals self-
report depression during their lifetime [2]. The most common
clinically recognised form of depression is called Major
Depressive Disorder (MDD). Both environmental and genetic
factors influence MDD. In particular, MDD is more com-
monly observed among individuals reporting exposure to
stressful life events and early-life traumas [3–6]. In turn,
reported trauma exposure has been robustly correlated with a
range of adverse life outcomes including MDD [6–9]. The
relationship between MDD and reported trauma exposure is
complex. Reported trauma exposure is associated with both
subsequent MDD and prior MDD [10, 11]. However, the
majority of people reporting exposure to traumatic experi-
ences do not report MDD [6–9].
Twin studies show that MDD is moderately heritable,
with 30–40% of the variance in MDD attributable to genetic
factors [12]. The proportion of heritability captured by
common genetic variants, also known as single nucleotide
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polymorphism or SNP-based heritability, can be estimated
from genome-wide association study (GWAS) data. Such
estimates tend to be lower than those obtained from twin
approaches, due to the incomplete capture of genetic
information in GWAS data among other reasons [13]. The
most recent major depression GWAS from the Psychiatric
Genomics Consortium was anchored in 35 cohorts
(including the 23andMe discovery cohort [14]) recruited
with a variety of methods [15]. This meta-analysis identified
44 loci significantly associated with major depression,
and estimated a SNP-based heritability of 9–10% [15].
These results strongly suggest both the mild and more
severe forms of depression are polygenic, with potentially
thousands of variants with very small individual effects
contributing to risk.
There are far fewer genetic studies of reported trauma
exposure than of MDD. However, the available studies have
demonstrated that reported trauma exposure is heritable,
with twin heritability estimates of 20–50% [16–18] and
SNP-based heritability estimates of 30% [19]. Combining
measures of trauma exposure and depression at scale is
difficult, given the need for careful phenotyping [20].
Potential confounds include the (often unavoidable) use of
retrospective self-reported measures of trauma exposure,
which can be weakly correlated with objective measures of
traumatic experiences [9]. Furthermore, current (i.e. state)
low mood can increase self-reporting of previous trauma
exposure [9, 21]. Previous individual study cohorts have
generally been too small for effective GWAS, while meta-
analyses have contained considerable heterogeneity due to
the use of different phenotyping instruments in the included
studies.
However, some notable genome-wide analyses of MDD
and trauma exposure have been performed. A genome-wide
by environment interaction study of depressive symptoms
and stressful life events in 7179 African American women
identified a genome-wide association near the CEP350 gene
(although this did not replicate in a smaller cohort) [22]. An
investigation in 9599 Han Chinese women with severe
MDD identified three variants associated with MDD in
individuals who did not report trauma exposure prior to
MDD onset [23].
Several attempts have been made to estimate the inter-
action of overall genetic risk and trauma by using polygenic
risk scores for MDD to perform polygenic risk score-by-
trauma interaction analyses. Such studies test whether there
are departures from additivity (where the combined effect of
risk score and trauma differs from the sum of the individual
effects) or from multiplicativity (where the combined effect
differs from the product of the individual effects). Reported
results have been highly variable, with findings of both
significant additive and multiplicative interactions [24];
significant multiplicative interactions only [25]; and, in the
largest previous study published (a meta-analysis of 5765
individuals), no interactions [26].
Studies of gene–environment interaction usually assume
the genetic and environmental influences are independent
and uncorrelated [27]. However, genetic correlations
between reported trauma exposure and MDD have been
reported, both from twin studies [28–30] and from the
genomic literature [22, 26]. Reports of the magnitude of this
genetic correlation have varied widely, which reflects dif-
ferences in defining trauma exposure, and in the populations
studied. While some studies have identified a very high
genetic correlation (95%) [22], others have found no such
correlation [23]. The genetic relationship between reported
trauma exposure and MDD is therefore unresolved.
The release of mental health questionnaire data from the
UK Biobank resource provides an opportunity to assess the
relationship between genetic variation, risk for MDD, and
reported trauma exposure in a single large cohort. We
performed GWAS of MDD (as defined from the mental
health questionnaire [31]) with and without reported life-
time trauma exposure in UK Biobank European ancestry
individuals. These results enabled us to estimate the genetic
contribution (via SNP-based heritability estimation) to
MDD in individuals with and without reported lifetime
trauma exposure. To examine differences in the genetic
contribution, we calculated the genetic correlation between
MDD in individuals reporting and not reporting trauma
exposure. To assess whether the genetic relationship of
MDD to other traits varies in the context of reported trauma
exposure, we assessed genetic correlations with a wide
range of physical and psychiatric traits. Finally, we per-
formed polygenic risk scoring, using external traits com-
monly comorbid with MDD, and sought to extend previous




The UK Biobank assessed a range of health-related phe-
notypes and biological measures including genome-wide
genotype data in ~500,000 British individuals aged between
40 and 70 [32]. This includes 157,366 participants who
completed an online follow-up questionnaire assessing
common mental health disorders, including MDD symp-
toms, and 16 items assessing traumatic events (Resource 22
on http://biobank.ctsu.ox.ac.uk) [31]. Phenotypes were
derived from this questionnaire, using definitions from a
recent publication describing its phenotypic structure [31].
Individuals with probable MDD met lifetime criteria
based on their responses to questions derived from the
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Composite International Diagnostic Interview (CIDI; Sup-
plementary Table 1). We excluded cases if they self-
reported diagnoses of schizophrenia, other psychoses, or
bipolar disorder. Controls were excluded if they self-
reported any mental illness, taking any drug with an anti-
depressant indication, or had been hospitalised with a mood
disorder or met previously-defined criteria for a mood dis-
order (Supplementary Table 1) [33].
Participants were asked questions relating to traumatic
experiences in childhood using the Childhood Trauma
Screener (a shortened version of the Childhood Trauma
Questionnaire [34–36]) and an equivalent screener for
adulthood developed by the UK Biobank Mental Health
steering group to mirror the childhood items [31]. In addi-
tion, participants were asked questions related to events that
commonly trigger post-traumatic stress-disorder (PTSD).
Responses to individual questions (items) in these three
categories (child trauma, adult trauma, PTSD-relevant
trauma) were dichotomised and compared between MDD
cases and controls (Supplementary Table 2a).
We selected reported items with an odds ratio >2.5 with
MDD, to obtain a single binary variable for stratification
that captured exposure to the traumatic events most
associated with MDD. Items from all three trauma cate-
gories were reported more in MDD cases compared with
controls. Of the selected items, three referred to events in
childhood (did not feel loved, felt hated by a family
member, sexually abused). Another three items referred to
events in adulthood (physical violence, belittlement,
sexual interference), and one item assessed a PTSD-
relevant event (ever a victim of sexual assault). In order to
capture increased severity of exposure, only individuals
reporting two or more of these items were included as
reporting trauma exposure. Individuals reporting none of
the items were included as not reporting trauma exposure.
Individuals reporting a single trauma item, or who did
not provide an answer were excluded from the
analyses (Supplementary Table 1). A breakdown of
reported traumatic experiences by sex and MDD status is
provided in Supplementary Table 2b. Further discussion
of the definition of trauma exposure is included in the
Supplementary Note.
Phenotype preparation for analyses
Three sets of analyses comparing MDD cases and controls
were performed (i) overall, (ii) limited to individuals
reporting trauma exposure, and (iii) limited to individuals
not reporting trauma exposure (Table 1). In addition, sen-
sitivity analyses were performed on reported trauma expo-
sure (overall and stratified by MDD diagnosis; see
Supplementary Methods and Results, and Supplementary
Table 3). For each analysis, phenotypes were first residua-
lised on 6 ancestry principal components from the genetic
data of the European samples as well as factors capturing
initial assessment centre and genotyping batch. More details
on phenotype preparation can be found in the Supplemen-
tary Methods.
Phenotype distribution
Previous analyses have shown that, compared with the
participants in the UK Biobank as a whole, those who
completed the mental health questionnaire were more likely
to have a university degree, came from a higher socio-
economic background, and reported fewer long-standing
illnesses or disabilities [31]. Accordingly, participants were
compared across a number of standard demographic vari-
ables and common correlates of MDD: sex, age (at ques-
tionnaire), education (university degree vs. not),
neighbourhood socioeconomic status (SES, as Townsend
deprivation index [37]) and BMI (recorded from measure-
ments taken at the initial recruitment of the participants into
the biobank). For further details on these analyses, see
Supplementary Methods.
Genetic data
Genetic data for GWAS analyses came from the full release
of the UK Biobank data (N= 487,410; [38]). Autosomal
genotype data from two highly-overlapping custom geno-
typing arrays (covering ~800,000 markers) underwent
centralised quality control before being imputed in a two-
stage imputation to the Haplotype Reference Consortium
(HRC) and UK10K (for rarer variants not present in the
Table 1 Participants available
for analysis
Participants with genomic data
Reported trauma exposure No reported trauma exposure Excluded Total
MDD Cases 13,393b 9487c 6595 29,475a
Controls 10,701b 39,677c 13,104 63,482a
Groups of individuals used in each of the three analyses are in bold
aMDD in all participants (29,475 cases, 63,482 controls, N= 92,957)
bMDD in participants reporting trauma exposure (13,393 cases, 10,701 controls, N= 24,094)
cMDD in participants not reporting trauma exposure (9487 cases, 39,677 controls, N= 49,164)
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HRC) reference panels [38–40]. In addition to this central
quality control, variants for analysis were limited to com-
mon variants (minor allele frequency > 0.01) that were
either directly genotyped or imputed from the HRC with
high confidence (IMPUTE INFO metric > 0.4) [39].
Individuals were excluded where recommended by the
UK Biobank core analysis team for unusual levels of
missingness or heterozygosity, or if they had withdrawn
consent for analysis. Using the genotyped SNPs, individuals
with call rate <98%, who were related to another individual
in the dataset (KING r < 0.044, equivalent to removing
third-degree relatives and closer [41]) or whose phenotypic
and genotypic gender information was discordant (X-chro-
mosome homozygosity (FX) < 0.9 for phenotypic males,
FX > 0.5 for phenotypic females) were also excluded.
Removal of relatives was performed using a “greedy”
algorithm, which minimises exclusions (for example, by
excluding the child in a mother–father–child trio). All
analyses were limited to individuals of European ancestry,
as defined by 4-means clustering on the first two genetic
principal components provided by the UK Biobank [42].
This ancestry group included 95% of the respondents to the
mental health questionnaire—as such, the non-European
ancestry groups were considered too small to analyse
informatively. Principal components analysis was also
performed on the European-only subset of the data using the
software flashpca2 [43]. After quality control, individuals
with high-quality genotype data and who had completed the
online mental health questionnaire were retained for ana-
lysis (N= 126,522).
GWAS analyses used the imputed data as described
above. Genetic correlation analyses used the results of the
GWAS analyses. Polygenic risk score analyses and SNP-
based heritability analyses in BOLT-LMM used the geno-
typed variants [38]. These latter analyses were limited to
common variants (minor allele frequency > 0.01) with call
rate > 98% that were in approximate Hardy–Weinberg
equilibrium (HWE test p > 10−8). The same individuals
were used for analyses using the imputed and the
genotyped data.
Analyses
Genome wide association studies (GWAS)
GWAS were performed to assess the association of indi-
vidual genetic variants with MDD. These analyses were first
undertaken for the entire sample regardless of reported
trauma exposure, then stratified by reported trauma expo-
sure. GWAS were performed using linear regressions on
imputed genotype dosages in BGenie v1.2 [38], with resi-
dualised phenotypes as described above. Phenotypes
and genotypes were mean-centred and standardised.
Genome-wide significance was defined at the conventional
level p < 5 × 10−8 [44]. Results from each GWAS were
clumped to define genetic loci in PLINK2 [45]. Loci were
defined following established protocols (Supplementary
Methods) [15].
Betas from the GWAS were converted to odds ratios
(OR) using LMOR (http://cnsgenomics.com/shiny/
LMOR/) and observed sample prevalences [46]. Stan-
dard errors were calculated from the p-value and esti-
mated OR [47]. Performing GWAS on residuals, rather
than including covariates in the analysis, is a restriction
imposed by the BGenie software (which was used because
it is specifically designed for analysing the UK Biobank
genetic data). Sensitivity analyses were performed to test
for biases resulting from this method. Specifically, for
each GWAS, each variant with nominal significance (p <
0.0001) was also tested using logistic regression including
covariates in R 3.4.1, in order to confirm the results from
BGenie [48].
SNP-based heritability
Results from GWAS were combined to assess the propor-
tion of variance due to the additive effect of common
genetic variants (SNP-based heritability). SNP-based herit-
ability was calculated on the observed scale using BOLT-
LMM v2.3 [49]. The estimate for MDD in the cohort was
converted to the liability scale in R 3.4.1, assuming a
population prevalence of 28% [2, 50]. Converting estimates
of SNP-based heritability for a case-control trait from the
observed scale to the liability scale requires accurate esti-
mates of the lifetime prevalence of the trait in the (sub)
population. When comparing a trait stratified by a correlated
variable (as is the case when we compare the SNP-based
heritability of MDD stratified by reported trauma exposure),
the population prevalence in each stratum is unknown. To
address this, we approximated the expected prevalence of
MDD in individuals either reporting or not reporting trauma
exposure (Supplementary Methods). This allowed us to
convert the observed scale SNP-based heritability of MDD
to the liability scale in both strata (i.e. those reporting and
those not reporting trauma exposure). A second challenge is
that trauma exposure is itself a heritable trait that is
genetically correlated with MDD in this study. The potential
impact of this on SNP-based heritability estimation is not
intuitive. To benchmark our findings, we performed simu-
lations of SNP-level data to explore the expected SNP-
based heritability of MDD in individuals reporting and not
reporting trauma exposure, assuming differences in SNP-
based heritability resulted only from the genetic correlation
between MDD and reported trauma exposure. Further
details of these analyses are provided in the Supplementary
Methods.
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Genetic correlations
Genetic correlations (rg) were calculated to assess shared
genetic influences between MDD and other phenotypes, using
GWAS summary statistics and LD Score regression v1.0.0
[51] using the default HapMap LD reference. Two sets of
genetic correlations were calculated. First, we calculated
genetic correlations between the phenotypes examined within
this paper (internal phenotypes). We calculated the genetic
correlation between MDD and reported trauma exposure in
the full dataset, and then the genetic correlation between
MDD in individuals reporting trauma exposure and MDD in
individuals not reporting trauma exposure. Secondly, we also
calculated genetic correlations between each GWAS from this
analysis and a curated list of 308 publicly-available pheno-
types (external phenotypes) [51, 52].
Genetic correlations were tested for difference from 0
(default in LD Score), and for difference from 1 (in
Microsoft Excel, converting rg to a chi-square as [(rg− 1)/
se]2) [51, 52]. Genetic correlations were considered sig-
nificant if they passed the Bonferroni-adjusted threshold for
the effective number of traits studied in each analysis
(internal: p < 0.01; external: p < 2.5 × 10−4). The effective
number of traits was calculated as the number of principal
components explaining 99.5% of the variance in the pair-
wise genetic correlation matrix (internal: 5; external: 202).
External phenotype GWAS all had heritability estimates
such that h2/SE > 2, and produced valid (i.e. non-NA) rg
with all other phenotypes tested.
The genetic correlation of MDD with each external
phenotype was compared between individuals reporting
trauma exposure and individuals not reporting trauma
exposure using a two-stage method. First, differences were
assessed using two sample z-tests [53]. Nominally-
significant differences (p < 0.05) by this method were then
compared using the block-jackknife (Supplementary
Methods) [52, 54, 55]. Results using the jackknife were
considered significant if they passed the Bonferroni-
adjusted threshold (p < 2.5 × 10−4).
Polygenic risk scoring
Polygenic risk scores were calculated to further assess
shared genetic influences between MDD and traits known to
be correlated to MDD. Specifically, risk scores from ana-
lyses of major depression (MDD) [15], schizophrenia (SCZ)
[56], bipolar disorder (BIP) [57], body mass index (BMI)
[58] and glycated haemoglobin (HbA1c; used as a negative
control) [59] were calculated and compared in all partici-
pants and stratifying by reported trauma exposure. The PGC
major depression GWAS contained participants from UK
Biobank, so to derive the MDD risk score we used a
restricted set of summary statistics without these individuals
(but including individuals from 23andMe, whose diagnoses
were self-reported [14]). For further discussion of this
overlap, see Supplementary Note [15]. Risk scores were
calculated using PRSice v2 at seven thresholds (external
GWAS p < 0.001, 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5) to allow
assessment of the spread of association between risk score
and MDD [45, 60, 61]. Analyses used logistic regression,
including all covariates used in creating the residuals for
GWAS. In total, five external phenotypes were used to
produce risk scores for the three target phenotypes (MDD
overall, and stratified by reported trauma exposure/non-
exposure), resulting in 15 analyses. A conservative Bon-
ferroni adjustment for multiple testing was used, correcting
for 105 tests (given seven thresholds and 15 analyses),
giving a final threshold for significance of p < 0.0004.
We also performed formal risk score-by-environment
analyses to estimate the effect on MDD of the interaction
between genetic variants across the whole genome (modelled
as a polygenic risk score) and reported trauma exposure.
These analyses included the same covariates used in the
GWAS, and all risk score-by-covariate and reported trauma
exposure-by-covariate interactions [62, 63]. Both multi-
plicative and additive interactions were tested. A significant
multiplicative interaction means that the combined effect of
the risk score and reported trauma exposure differs from the
product of their individual effects. Multiplicative interactions
were tested using logistic regression [25, 26]. A significant
additive interaction means that the combined effect of the risk
score and reported trauma exposure differs from the sum of
their individual effects. Additive interactions were tested
using linear regression (Supplementary Methods).
Sensitivity analyses
Differences in phenotypic variables were observed between
cases and controls. To assess the impact of including these
variables as covariates, all analyses were rerun retaining all
previous covariates and including as further covariates: age (at
questionnaire), neighbourhood socioeconomic status (SES, as
Townsend deprivation index [37]), BMI (at baseline assess-
ment), and a binary variable of education (university degree
vs. not). The same covariates were also included in polygenic
risk score and SNP-based heritability analyses. Sensitivity
analyses focussing on reported trauma exposure as an out-
come were similarly rerun (Supplementary Methods).
The majority of the sample with data on both MDD
symptoms and reported trauma status were controls who did
not report trauma (Table 1). To assess whether this dis-
balance in sample status affected our results, genetic cor-
relation analyses with external phenotypes were rerun on
ten downsampled cohorts, with 9,487 participants in each
group (the number of cases not reporting trauma exposure;
see Supplementary Methods).
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In order to test whether our definition of trauma exposure
affected the main finding of our paper, we performed three
further sensitivity analyses, redefining reported trauma expo-
sure. First, we assessed if our main finding was robust to
changing the threshold for including MDD-relevant trauma,
by redefining reported trauma exposure as a report of (i) one
or more and (ii) three or more of the seven MDD-relevant
trauma items. Second, we assessed whether the timing of
trauma exposure affected this finding by redefining reported
trauma exposure as a report of (iii) one or more of the five
childhood trauma items. We then re-analysed the heritability
of MDD in individuals reporting and not reporting trauma
exposure using these three alternative definitions.
Results
Phenotype distribution
Phenotypic and genetic data were available on
24,094–92,957 individuals (Table 1). Overall, 36% of
individuals met our definition of MDD-relevant trauma
exposure, and were more frequently cases (45%) than
controls (17%; OR= 5.23; p < 10−50, chi-square test). We
assessed a number of phenotypic correlates of depression to
confirm that these correlates differed between MDD cases
and controls, and to assess whether these differences were
affected by trauma exposure. Cases differed significantly
from controls overall. Individuals with MDD were mostly
females, significantly younger, less likely to have a uni-
versity degree, came from more deprived neighbourhoods,
and had higher BMI at recruitment. These differences per-
sisted when the cohort was limited just to individuals
reporting trauma exposure, and when the cohort was limited
just to individuals not reporting trauma exposure. Further-
more, cases reporting trauma exposure differed from cases
not reporting trauma exposure, in that they were mostly
females, younger, more likely to have a degree (note dif-
ference from case-control comparisons), came from more
deprived neighbourhoods, and had higher BMI at recruit-
ment. The same differences (in the same direction) were
observed between controls reporting and not reporting
trauma exposure (all p < 0.05; Supplementary Table 4).
Genome-wide association studies
We performed GWAS for MDD overall and stratified by
reported trauma exposure to obtain results for heritability
and genetic correlation analyses (Supplementary Table 5;
Supplementary Figs. 1–3). No analysis showed evidence of
genome-wide inflation attributable to confounding (the 95%
confidence intervals of all regression intercepts from LD
Score included 1; Supplementary Table 6). One genome-
wide significant locus (rs11515172, Chr 9:11 Mb, p=
3.82 × 10−8) was identified in the analysis of MDD overall,
and remained significant when using logistic regression
(p= 4.69 × 10−8, OR= 0.96, SE= 0.007; Supplementary
Table 5). This locus has been repeatedly associated with
depression [15, 64, 65], and with neuroticism [66–69].
However, it should be noted that all of these studies
included UK Biobank. The locus is intergenic, and is not
annotated to any currently known biological feature of
interest (Supplementary Table 7).
SNP-based heritability
First we estimated the observed scale SNP-based herit-
ability of MDD overall and stratified by reported trauma
exposure. Second, in order to assess whether the relative
influence of genetic variants on MDD differed by reported
trauma status, we converted SNP-heritabilities to the liabi-
lity scale. We assumed a prevalence of 28% for self-
reported MDD in the full population [2]. Based on this, and
on the ratio of MDD cases:controls in the sample, we
estimated the prevalence of MDD in the trauma-exposed
population as 52%, and in the unexposed population as
17%. Using these estimates of population prevalence, the
liability scale estimate of MDD SNP-based heritability was
20% (95% confidence interval: [18–22%]) overall. In those
reporting trauma exposure, the liability scale SNP-based
heritability of MDD was 24% [18–31%], and in those not
reporting trauma exposure it was 12% [7–16%]. The SNP-
based heritability of MDD was significantly greater in
individuals who reported trauma exposure compared to
those who did not (p= 0.0021, Z-test).
These estimated SNP-heritabilities could be confounded
by genetic correlation between MDD and reported trauma
exposure. We designed and conducted simulations of SNP-
level data to quantify the expected difference in SNP-based
heritability from genetic correlation alone (Supplementary
Methods). Our simulations yielded expected estimates for
the liability scale SNP-based heritability of MDD of
14–15% in those reporting trauma exposure, and 15–16% in
those not reporting trauma exposure (Supplementary
Methods). This small difference in expected SNP-based
heritability for those reporting and not reporting trauma is in
the opposite direction to our findings. This suggests that our
findings cannot be explained by genetic correlation between
MDD and reported trauma exposure, nor by the transfor-
mation from the observed scale to the liability scale.
Genetic correlations
Genetic correlations were calculated between MDD and
reported trauma to explore the genetic relationship between
these traits. Further genetic correlations were calculated
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between MDD in the two strata to assess whether genetics
influences on MDD differ in the context of reported trauma
exposure (Supplementary Table 8).
We observed a significant rg between MDD and reported
trauma exposure in the full cohort (0.62 [95% CI:
0.76–0.94], p < 10−50). Given that trauma items were
selected for association with MDD, we also calculated the
genetic correlation between MDD in the full cohort and
reported trauma exposure in just the controls, which was
also significant (0.31 [0.18–0.45], p= 4 × 10−6; Supple-
mentary Table 8). This correlation persisted when using
independent major depression GWAS summary statistics,
as reported trauma exposure was significantly correlated
with the MDD polygenic risk score (Spearman's rho=
0.0675, p < 10−50) [15]. The genetic correlation between
MDD in individuals reporting trauma exposure and MDD in
individuals not reporting trauma exposure was high and
did not differ significantly from 1 (rg= 0.77 [0.48–1.05];
difference from 0: p= 1.8 × 10−7; difference from 1:
p= 0.11).
Genetic correlations were calculated between MDD and
all available external traits to systematically assess whether
genetic relationships with MDD differed in the context of
reported trauma exposure. All psychiatric traits included
were significantly associated (p < 2.5 × 10−4) with MDD,
but this association did not differ substantially in magnitude
between the groups reporting and not reporting trauma
exposure (z-test for comparisons of rg−Δrg—ranged from
p= 0.10–0.99; Fig. 1). In contrast, waist circumference was
significantly associated with MDD only in individuals
reporting trauma exposure (rg= 0.24), and the correlation
was significantly larger than that in individuals not reporting
trauma exposure (rg=−0.05, jackknife pΔrg= 2.3 × 10−4).
Other correlations between MDD and body composition,
reproductive, and socioeconomic phenotypes were larger in
the group reporting trauma exposure compared to indivi-
duals not reporting trauma exposure, but these differences
did not remain significant following multiple testing cor-
rection (all jackknife p > 2.5 × 10−4; Fig. 1, Supplementary
Table 9).
Polygenic risk scores across strata
We performed polygenic risk score analyses to further
explore how stratification by trauma status affects the
genetic relationship between MDD and specific correlates
of MDD, and to mirror previous analyses in the literature
(Fig. 2, Table 2; see Supplementary Table 10 for full details
of all risk score analyses, including the number of SNPs in
each score) [26]. Individuals with high genetic risk scores
for MDD were more likely to be cases than controls, and a
significant additive interaction term was observed from
linear regression. Specifically, the combined effect of the
MDD risk score and reported trauma exposure on MDD
was greater than the sum of the individual effects (beta > 0,
Table 2 central panel). However, the multiplicative inter-
action term was not significant (p > 0.01). The presence of
an interaction on the additive scale reflects the greater SNP-
based heritability of MDD in individuals reporting trauma
exposure (SNP− h2= 24%) compared with those not
Fig. 1 Genetic correlations between MDD (overall and stratified by
reported trauma exposure) and selected traits and disorders. Full
genetic correlation results are available in Supplementary Table 9.
Numbers= genetic correlations. Colour= direction of effect (blue=
positive, red= negative). Colour intensity= size of correlation. Upper
and lower bars are 95% confidence interval of genetic correlation
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reporting trauma exposure (SNP− h2= 12%), as described
above.
In contrast, although those with higher BMI risk scores
were more likely to be cases than controls, this only passed
correction for multiple testing in individuals reporting
trauma exposure. Both the additive (beta > 0) and the mul-
tiplicative (OR > 1) interaction terms were significant, sug-
gesting the combined effect on MDD from BMI risk score
and reported trauma exposure together was greater than
expected from both the sum of the individual risks and from
their product, respectively (OR > 1).
Individuals with high genetic risk scores for SCZ were
more likely to be cases than controls, but this did not differ
between strata (both interaction terms p > 0.01). Individuals
with higher BIP risk scores were also more likely to be
cases than controls—although this association was not
Fig. 2 Association between MDD polygenic risk score (PRS) and
MDD. Individuals reporting trauma exposure are shown as orange
triangles, and those not reporting trauma exposure as green dots.
a shows the relationship on the linear additive scale, and b shows the
relationship on the multiplicative scale. A significant interaction is
observed on the additive scale only, as shown by differing slopes of
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significant in the subset of individuals reporting trauma
exposure, no significant interaction term was observed,
suggesting the observed difference in results within-strata
may be due to differences in power. No significant differ-
ences were observed in the negative control analysis
with HbA1c.
Sensitivity analyses
Four sets of sensitivity analyses were performed. In the first
set, all analyses were repeated using reported trauma
exposure as the phenotype, assessed overall and stratified by
MDD (as opposed to the primary analysis, where MDD was
the phenotype and analyses were stratified by reported
trauma exposure). Results from these analyses were broadly
similar to the results from the primary analysis (Supple-
mentary Tables 3–11, Supplementary Figs. 4–7).
The second set of sensitivity analyses repeated the pri-
mary analyses with additional covariates to assess the
impact of controlling for age, neighbourhood socio-
economic status, BMI, and education. This did not alter the
conclusions drawn from the GWAS and SNP-based herit-
ability analyses, nor from the genetic correlations observed
between the internal phenotypes (those assessed in this
study; Supplementary Tables 12–17). Genetic correlations
between MDD and external phenotypes did not differ sig-
nificantly from the main analysis (all z-test p < 0.05), but
were sufficiently attenuated that the genetic correlations of
MDD with waist circumference was no longer significantly
different between individuals reporting and not reporting
trauma exposure. Differences in the polygenic risk score
analyses were limited to analyses involving the BMI risk
score. In analyses adjusted for phenotypic BMI, the BMI
polygenic risk score was no longer associated with MDD in
any analysis, and no interactions including the BMI risk
score remained significant.
The third set of sensitivity analyses repeated the genetic
correlation analyses, but downsampled the analysed cohort
such that each of the four groups (MDD cases/controls
reporting/not reporting trauma exposure) had 9487 partici-
pants (the size of the smallest group from the main analysis,
cases not reporting trauma exposure). In these analyses,
genetic correlations between MDD and external phenotypes
were attenuated across most phenotypes, but not sig-
nificantly (two-sample z-tests, all p > 0.05; Supplementary
Table 18). As such, the general pattern of genetic correla-
tions observed in the main analysis was retained, although
the genetic correlations of MDD with waist circumference
was no longer significantly different between individuals
reporting and not reporting trauma exposure.
The final set of sensitivity analyses repeated the SNP-
based heritability analyses of MDD in individuals reporting
and not reporting trauma exposure, altering the definition of
reported trauma exposure in three ways (increasing and
decreasing the number of items required to be defined as
reporting trauma exposure, and limiting the items con-
sidered to only childhood experiences). The purpose of
these analyses was to test the robustness of our key finding
(greater MDD SNP-based heritability in trauma-exposed
individuals compared with those not reporting trauma
exposure). Neither increasing nor decreasing the number of
MDD-relevant items selected, nor focussing on childhood
items, altered our conclusions (Supplementary Table 19).
Full results for all four sensitivity analyses, and for
variant-level gene-by-environment interaction analyses
(Supplementary Table 20), are included in the Supple-
mentary Material.
Discussion
We investigated the relationship between MDD and self-
reported trauma exposure in the largest single cohort
available to date (N= 73,258 with MDD and reported
trauma data). The SNP-based heritability of MDD was
higher in individuals reporting trauma exposure than in
individuals not reporting trauma exposure. This was not
explained by gene–environment correlation, or the trans-
formation of SNP-based heritability from the observed to
the liability scale. Despite the significant difference in SNP-
based heritability across the two strata, the genetic corre-
lation between MDD in individuals reporting and not
reporting trauma exposure was not statistically different
from 1. Polygenic risk score-by-reported trauma exposure
interaction analyses identified significant interactions for
both MDD and BMI risk scores. However, the interactions
involving the BMI risk score appear to be explained by
differences in measured BMI between MDD cases and
controls. Finally, a significant genetic correlation between
MDD and waist circumference was observed only in indi-
viduals reporting trauma exposure, and was absent from
those not reporting trauma exposure.
A number of limitations should be considered when
assessing our results. Our simulations suggest that our SNP-
based heritability differences did not result from
gene–environment correlation between MDD and reported
trauma exposure, nor the conversion of observed scale SNP-
based heritabilities to the liability scale. However, we could
not address further sources of potential bias. These could
arise from non-additive genetic architectures, ascertainment
bias and the effects of covariates not included in the model
[70, 71], or from potential collider bias resulting from
selection bias [72]. We also assumed that the population
prevalence of reported trauma exposure can be extrapolated
from that observed in this sample (see Supplementary
Methods). Although the UK Biobank allows us to integrate
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genetic and environmental data at scale, and is a reasonably
homogeneous cohort, it also has a “healthy volunteer bias”,
whereby the participants tend to have better overall health
and higher socioeconomic status compared with the
equivalent overall population of this age [73]. It is possible
that the depressive and traumatic experiences reported by
these participants may not generalise to the whole popula-
tion, or to clinically-ascertained cases. Furthermore, we
focussed on European ancestry; further studies in non-
European populations are required [74].
To obtain further insight into the association of genome-
wide genetic variation and reported trauma exposure
with MDD (and to enable comparison with previous studies
[24–26]), we carried out polygenic risk score-by-
environment interaction analyses. There are a number of
limitations to consider when interpreting such analyses.
Polygenic risk score-by-environment interaction analyses
test a specific hypothesis, namely that the overall associa-
tion of common variants with the outcome (modelled as a
risk score) varies dependent on the environmental exposure
being tested. We did not test the existence of specific
variant-by-environment interactions, including those fea-
turing variants contributing to the risk score. Furthermore,
we cannot exclude the possibility that the correlation
between the MDD and BMI risk scores with reported
trauma exposure may alter the observed interactions. This
prevents the drawing of strong conclusions, especially given
the limited predictive power of the risk scores used in this
study (Supplementary Table 10).
Throughout this paper, we have referred to our depres-
sion phenotype as “MDD” rather than “major depression”.
We do this because our definition is based on the CIDI-SF,
which has previously been shown to have good con-
cordance with direct clinical assessments of MDD [75, 76].
However, it should be noted that direct assessment was not
performed, and our MDD cases may not have met criteria
within a clinical setting. Nonetheless, genetic correlations
between studies of clinical MDD and our definition are very
high, suggesting there is strong genetic continuity across
different methods of assessing depression [15, 65].
Trauma exposure was defined in this study using retro-
spective self-report. This is not the ideal measure for this
phenotype, and precludes robust measurement of the
severity and timing of the reported trauma exposure.
However, retrospective report is the only feasible option for
cohorts large enough to enable detailed genetic analyses of
the interaction between trauma and MDD. Retrospectively
reported trauma and MDD are also not robust to reverse
causation, and our results cannot strongly inform any tem-
poral or causal hypotheses about their relationship. Such
hypotheses could be tested using (extensive) longitudinal
studies or through more powerful genomic studies of
trauma exposure including data from similar or larger
cohorts. This could enable the identification of sufficient
robustly associated genetic variants to inform approaches
such as Mendelian randomisation (which we were under-
powered to examine in this study). In addition, future work
may benefit from assessing the heritability of broader
depression phenotypes that lie beyond our binary criteria,
including reward sensitivity and negative valence traits [77].
Our findings suggest that the genetic variants associated
with MDD are the same in individuals reporting and not
reporting trauma exposure, because the genetic correlation
between MDD measured in these two groups was not sig-
nificantly different from 1. However, the SNP-based herit-
ability of MDD was greater in individuals reporting
compared to not reporting trauma exposure. This suggests
that the combined effect of the variants associated with
MDD is greater in people reporting trauma exposure than in
those who do not. The mechanism underlying this finding is
uncertain. One possibility is that exposure to traumatic
events might amplify genetic influences on MDD beyond
the magnitude of the effects seen in the absence of trauma
(consistent with the stress-diathesis hypothesis [78–80]).
The concept that genetic variance varies with exposure to
different environments is well-recognised in studies of
animal populations in the wild [81]. However, the opposite
may also be true; genetic influences on MDD could increase
an individual's likelihood of experiencing and/or reporting
trauma, and through doing so increase the apparent herit-
ability of MDD by partly incorporating genetic influences
related to trauma reporting itself [11]. A third possibility
relates to the components of variance involved in calculat-
ing SNP-based heritability. Phenotypic variance can be
attributed either to the SNPs measured in the GWAS, or to
environmental sources of variance reflecting all phenotypic
variance not explained by common variants. It is possible
that the genetic variance is constant across the strata, but
that the environmental variance is decreased when only
considering individuals reporting trauma exposure, due to
the shared (and thus more similar/less variable) exposure of
these individuals to MDD-relevant traumatic experiences.
This would result in greater heritability in individuals
reporting trauma exposure. These explanations are potential
interpretations of these findings but are not the only possi-
bilities. It is also likely that multiple such mechanisms are
involved.
A final, separate, possibility is that self-report is impaired
in the group reporting trauma exposure. Reported trauma
exposure is associated with an increased prevalence of
multiple psychiatric disorders including personality dis-
orders. The rapidly fluctuating symptoms of personality
disorders can reduce the reliability of self-report in affected
individuals [82]. If self-report is less reliable in those
reporting trauma exposure, this would affect the accuracy of
our MDD definition in this group, such that the cases in this
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group may also include unreported cases of excluded dis-
orders with higher heritability, such as bipolar disorder or
schizophrenia. Although the reported prevalence of per-
sonality disorder diagnosis in this cohort is too low to
explain the observed differences in SNP-based heritability
(142/22,880 MDD cases, <1% of MDD cases), the parti-
cipants in the study have not undergone more extensive
assessment, and further diagnoses of personality disorders
may have been missed.
In polygenic risk score-by-reported trauma exposure
interaction analyses, we identified a significant interaction
on the additive scale for the combined effect of the MDD
risk score and reported trauma exposure on risk of MDD.
These results are also reflected in the larger SNP-based
heritability of MDD in exposed compared to unexposed
individuals. The simplest explanation for this result is that
the effects of the MDD risk score and reported trauma
exposure on MDD combine multiplicatively, such that
their combined effects are greater than the sum of their
individual effects. For the BMI risk score however, the
interaction with reported trauma exposure appears to be
more complex, combining neither additively nor multi-
plicatively. In sensitivity analyses controlling for BMI
(obtained at recruitment, approximately five years before
the mental health questionnaire), the BMI risk score-by-
reported trauma exposure interaction was no longer sig-
nificant, suggesting that the observed interaction can be
explained by differences in measured BMI. Further
research, with concurrent measurements of BMI, trauma
exposure and MDD in a longitudinally-sampled cohort
would offer further insight into the relationship between
these three variables.
The high genetic correlation between MDD in indivi-
duals reporting and not reporting trauma exposure was
supported by significant genetic correlations between MDD
and other psychiatric disorders regardless of reported
trauma exposure. In individuals reporting trauma exposure,
a further significant genetic correlation was observed
between MDD and waist circumference, which was sig-
nificantly greater than the equivalent correlation in those not
reporting trauma exposure. Although not significant, there
was also a general pattern of higher genetic correlations
between MDD and several weight-related measures and
educational attainment, in individuals reporting trauma
exposure. This is consistent with previous literature on
traumatic experiences and related phenomena such as
Adverse Childhood Experiences, which has found that they
are associated not only with psychiatric risk but also with
wide-ranging impairments in social and health outcomes
including obesity and (less) education [83–86]. However,
we stress that causal conclusions cannot be drawn from
these (or our) data, or that the reported trauma exposure is
responsible for the observed differences.
Our estimate of the SNP-based heritability of MDD
(20%) is higher than that reported in previous studies of
major depression (~9%) [15]. This may be explained by the
relative homogeneity of the UK Biobank compared to
previous meta-analyses. The UK Biobank is a single-
country cohort ascertained using a consistent protocol. The
same questionnaire was used to gather symptom data, and
the samples were stored, extracted, and genotyped using a
single method. In contrast, meta-analyses have needed to
combine diverse ascertainment, sampling, and genotyping;
SNP-based heritability has been reported to decrease with
increasing numbers of meta-analysed samples [87].
Previous analyses have assessed alternative depression
phenotypes in the UK Biobank [65]. Our MDD phenotype
(based on DSM criteria for MDD) is most similar to the
probable MDD phenotype from Howard et al, rather than
the less strictly-defined "broad depression" phenotype,
which includes those who seek treatment for depression,
anxiety and related phenotypes. Our summary statistics
LDSC-based estimate is higher than the equivalent from
Howard et al (4–5%). However, our estimate using geno-
type data (20%) is within the bounds of equivalent estimates
by geographic region reported for the probable MDD
(0–27.5%) phenotype. We note that our MDD phenotype
definition may have more specificity than the probable
MDD phenotype used in Howard et al.
Our results also differ in several respects from those of a
study of MDD and adversity in Han Chinese women [23].
No difference in the SNP-based heritability of MDD
between individuals reporting and not reporting trauma
exposure was observed in the previous study, and we did
not replicate individual variant results. However, this is
unsurprising, as there are a number of differences between
the studies of which the primary one is sample size (this
study: 73,258; CONVERGE: 9599). Other differences
included culture and ethnicity, and the deeper phenotyping
methodology applied in CONVERGE, resulting in a severe
inpatient MDD phenotype. Notably, the previous study did
not report a genetic correlation between MDD and trauma
exposure [23].
Sensitivity analyses focussed on trauma found that self-
reported traumatic experience was significantly heritable, as
has been previously observed [19]. We strongly emphasise
that this does not necessarily imply that traumatic experi-
ences themselves have a biological component—such
experiences may be associated with other significantly
heritable traits, and their biology would then be reflected in
the observed heritability of trauma exposure. One potential
set of heritable traits that may be associated with reporting
traumatic experiences are personality traits such as risk-
taking, and this might explain the observed genetic corre-
lations with psychiatric traits. A similar phenomenon has
been proposed to underlie observed genetic correlations
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with socioeconomic status [88]. Our trauma exposure
measure relies on retrospective self-report, which is itself
correlated with personality traits and mood at time of report
[9]. This may also explain the genetic correlations we
observe with reported trauma exposure (including in con-
trols, who do not report previous psychiatric illness).
In summary, we find that genetic associations with MDD
in UK Biobank vary by context. Specifically, the SNP-
based heritability of MDD is larger in individuals reporting
trauma exposure compared to those not doing so. Further-
more, the genetic correlation of MDD with waist cir-
cumference was significant only in individuals reporting
exposure to trauma. Nonetheless, a strong genetic correla-
tion was observed between MDD measured in the two
strata. Together, these findings suggest the relative con-
tribution of genetic variants to variance in MDD is greater
when additional risk factors are present.
Code availability
Analytical code underlying this project will be made
available at https://github.com/tnggroup.
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